The research by Professor Felsher from Stanford School of Medicine has been instrumental in our understanding of the link between Myc and the immune system. The articles Myc helps Cancer Hide [published 10/03/16] and Protein increases signals that protect cancer cells [published 10/03/17] highlights the role of Myc in hosing down the immune response to tumor cells and the proliferation of tumors.
The presentation by Felsher, Oncogene Addiction: A Paradigm for Cancer Discovery and Therapeutics highlights the therapeutic necessity to inactivate Myc in order to allow the immune system to do its job.
Get Myc is the horse that should be driving the cart of cancer treatments that is Immuno-Oncology. We know that Myc is implicated in more than 7 in 10 cancer cases including breast, lung, stomach, cervical and colon tumors. Is it possible that in putting the cart before the horse, immuno-oncology has come up short in delivering the best outcomes for cancer patients?
What would a Myc inhibitor be worth? It would appear that the pre-clinical deal between Bristol Myers Squibb and Flexus for US$1.25B including an upfront US$800m is relevant for valuation purposes.
PYC Price at posting:
4.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)